Expanding Orthopedics, Inc. (EOI) has announced that Jonathan Lewin, M.D. of North Shore Forest Hills Hospital in New York is the first surgeon in New Jersey to adopt the FLXfit articulated and lordotic expandable cage as his choice of treatment for MIS TLIF (transforaminal lumbar interbody fusion) surgery.
EOI: First Implantation of FLXfit in New Jersey
1 min read Premium comments
Secondary
Dr. Lewin, director of spine surgery at North Shore Forest Hills Hospital and director of the Center for Musculosketal Disorders in Englewood, New Jersey, stated in the February 1, 2016 news release, “I was immediately impressed by the FLXfit’s immense footprint and was excited to finally be able to insert a big cage from the back through a MIS single portal incision. The FLXfit is the only cage available on the market that dials in lordosis within the disc space. This enables us to offer every patient a customized implant that will adapt to the patient’s unique anatomy and provide the best possible fit and stability.”
Dr. Lewin added, “We are excited to adopt advanced new technologies for MIS [minimally invasive spine] surgery as we have expanded our practice with the addition of Dr. Seth Grossman and Dr. Vigmin Vora to cope with the increased demand for our services. Our goal is to become one of the leading MIS spine surgery teams in New Jersey. The adoption of such unique MIS technologies enables us to offer our patients the best possible treatment options leading to faster recovery.”
Ofer Bokobza, CEO of Expanding Orthopedics, said, “We are excited to collaborate with Dr. Lewin and his team and congratulate them for joining a growing list of spine surgeons selecting the FLXfit as their new standard of care.”
Dr. Lewin told OTW, “I was very impressed with the enormous footprint of the cage as well as its lordotic features. We have been searching for an expandable device to rival the ALIF in a minimally invasive context. We believe this device has tremendous potential to achieve interbody fusion, while minimizing surgical trauma. The company is to be congratulated for its attention to surgeon need and detail.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.